In a nutshell This study investigated the effectiveness and safety of the R-B (rituximab, bendamustine) regimen versus the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen in patients with grade 3A follicular lymphoma (FL3A). This study concluded that R-B is better tolerated and more effective than R-CHOP, making it a...
Read MoreIn a nutshell This paper reviewed the adverse (negative) events associated with new treatments in multiple myeloma. Patients should be closely monitored for adverse events. Some background Multiple myeloma is a cancer of the plasma cells (type of white blood cell). Treatment includes the use of various types of medications. Adverse events...
Read More
In a nutshell This paper studied the risk of adverse events in patients who receive treatment for multiple myeloma. The use of new drugs increased the risk of low blood count, peripheral neuropathy and blood clots. Some background Multiple myeloma is a cancer of the plasma cells (type of white blood cell). Multiple myeloma can be treated with drugs...
Read MoreIn a nutshell This study aimed to investigate if side effects of imatinib (Gleevec) treatment in chronic phase chronic myelogenous leukemia would improve if patients were switched to dasatinib (Sprycel) treatment. This study concluded that these patients experience improvements in side effects and quality of life once they switch treatment. Some...
Read More
In a nutshell This study investigated the optimal time to start chemotherapy after colon surgery. Researchers suggested that patients should start chemotherapy within 8 weeks after surgery. Some background The recommended treatment for stage 3 colon cancer is surgery followed by chemotherapy. This reduces the risk of recurrence (when the cancer comes...
Read More
In a nutshell This study aimed to compare different strategies of promoting bone health. This study found that educational strategies to improve bone health care are feasible and are associated with improved bone mineral density ordering in men receiving androgen deprivation therapy. Some background Bone health is important for men receiving...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of nilotinib (Tasigna) in patients with chronic phase chronic myeloid leukemia who have an intolerance to other tyrosine kinase inhibitors. This study concluded that this group of patients can be treated with nilotinib and it can lead to deep molecular responses. Some background...
Read MoreIn a nutshell This study looked at the outcomes for patients with stage I follicular lymphoma who had their tumors completely removed. The authors concluded that a total resection does not significantly improve patient outcomes after they have received other treatments. Some background Follicular lymphoma (FL) is a type of slow growing non-Hodgkin...
Read More
In a nutshell This study looked at the effectiveness of treating elderly lymphoma patients with autologous stem cell transplantation. The study concluded that autologous stem cell transplantation should be considered on an individual basis, and age should not automatically disqualify elderly patients. Some background Patients with lymphoma...
Read More
In a nutshell This study looked at the effectiveness of treating elderly lymphoma patients with autologous stem cell transplantation. The study concluded that autologous stem cell transplantation should be considered on an individual basis, and age should not automatically disqualify elderly patients. Some background Patients with lymphoma...
Read More
In a nutshell This study outlined recent evidence on the use of ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL). Some background Tyrosine kinase inhibitor therapy is a type of immunotherapy that blocks signals needed for tumors to grow. This includes the Bruton tyrosine kinase inhibitor ibrutinib. Ibrutinib blocks a signal that keeps the...
Read More
In a nutshell This study examined treatment responses to imatinib (Glivec) in chronic myeloid leukemia (CML) patients. Researchers reported that about half of patients achieved an optimal response to treatment that could allow patients to safely stop therapy. Some background Molecular response (MR) is a response to treatment where hardly any or no...
Read More
